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Stem cells reside in niches that regulate the
balance between self-renewal and differentiation.
The identity of a stem cell is linked with the ability
to interact with its niche through adhesion mecha-
nisms. To identify targets that disrupt cancer
stem cell (CSC) adhesion, we performed a flow
cytometry screen on patient-derived glioblastoma
(GBM) cells and identified junctional adhesion
molecule A (JAM-A) as a CSC adhesion mechanism
essential for self-renewal and tumor growth. JAM-A
was dispensable for normal neural stem/progeni-
tor cell (NPC) function, and JAM-A expression
was reduced in normal brain versus GBM. Tar-
geting JAM-A compromised the self-renewal of
CSCs. JAM-A expression negatively correlated to
GBM patient prognosis. Our results demonstrate
that GBM-targeting strategies can be identified
through screening adhesion receptors and JAM-A
represents a mechanism for niche-driven CSC
maintenance.CINTRODUCTION
Stemcells are essential for the growth and homeostasis of organs
and, more broadly, an organism. Whereas stem cells have an
unlimited proliferation capacity and can differentiate into any
cell type in a given organ, they reside in specific anatomical loca-
tions or niches that ensure thecorrect balanceof self-renewal and
differentiation. Stem cells must be simultaneously maintained for
long-term tissue preservation yet constrained to avoid oncogen-
esis. Stem cells that exit a niche undergo differentiation and fate
determination. Niche signaling via secreted factors, cell-to-cell,
and cell-to-extracellular-matrix (ECM) interactions represent a
powerful control mechanism for stem cell regulation. Many niche
factors have also been implicated in the progression of advanced
cancers in the context ofmaintaining a self-renewing, tumorigenic
cancer stemcell (CSC)populationat the topof acellular hierarchy.
Like normal stem cells, CSCs also reside in distinct anatomical
locations and rely on niche interactions to regulate the balance
between self-renewal and differentiation, and these interactions
provide prosurvival and therapeutic resistance mechanisms
(Gilbertson and Rich, 2007; Spradling et al., 2001).
Whereas the CSC hypothesis remains controversial, CSCs
have been well documented in many advanced cancers,
including glioblastoma (GBM; World Health Organizationell Reports 6, 117–129, January 16, 2014 ª2014 The Authors 117
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grade IV glioma). Current therapeutic approaches for GBM
remain only palliative, and the standard care of surgical resec-
tion followed by aggressive radiation and chemotherapy has
extendedmedian survival to between 12 and 15monthswhereas
the 5-year survival remains approximately 2% (Stupp et al.,
2009). GBM is refractory to the current standard therapies partly
due to invasion into the normal brain and cellular heterogeneity
(Bonavia et al., 2011). The identification of CSCs in GBM (Galli
et al., 2004; Hemmati et al., 2003; Ignatova et al., 2002; Singh
et al., 2003, 2004) has generated enthusiasm for the integration
of CSCs into models of cancer (Visvader and Lindeman, 2012)
and the development of anti-CSC therapies. CSCs in GBM are
contained within hypoxic (Li et al., 2009) and perivascular niches
(Calabrese et al., 2007). The perivascular niche is readily identifi-
able in vivo, and efforts are underway to characterize the compo-
nents regulating this niche which include local mitogens, cell-cell
communication mechanisms, and unique structural compo-
nents, such as ECM proteins (Hjelmeland et al., 2011). We previ-
ously demonstrated that integrin a6, an ECM receptor, can be
used to enrich and target CSCs (Lathia et al., 2010). Additionally,
interaction with the specialized ECM of the perivascular niche,
which is provided by niche components, also promotes CSC
growth (Lathia et al., 2012). These studies provide a paradigm
for CSC maintenance whereby adhesion status is a determining
factor for the position of a cell within the tumor hierarchy, with
CSCs displaying an enhanced adhesion capacity as compared
to their differentiated progeny.
Whereas similarities exist between CSCs and nonneoplastic
stem cells, specific targets for CSCs have been generated by
comparing the molecular machinery between the cell types
and have been validated in preclinical models (Eyler et al.,
2011; Guryanova et al., 2011). However, niche adhesion targets
have yet to be developed. The interaction between cell-adhesion
mechanisms, including integrins, generates diverse signaling
responses based on cell type, location, and the cluster of recep-
tors present in a signaling complex. Defining adhesion-specific
programs unique to the CSC niche compartment is difficult as
many of these programs exist both in the normal and neoplastic
niches (Hale et al., 2012). For example, integrin expression and
function in organs, such as the brain and the breast, are similar
in the normal and neoplastic context, with both normal stem cells
and CSCs being enriched on the basis of integrin a6 (Ali et al.,
2011; Hall et al., 2006; Lathia et al., 2010; Shackleton et al.,
2006; Stingl et al., 2006), which plays a key role in regulating their
growth (Kazanis et al., 2010; Lathia et al., 2010; Loulier et al.,
2009). Given the importance of niche adhesion to stem cell main-Figure 1. High-Throughput Screening on GBM Specimens with a Mult
Correlated to GBM Patient Survival
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(D) Representative immunohistochemical data generated for CD321 and CD6
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See also Table S1 and Figure S1.
Ctenance (Niola et al., 2012, 2013), identification of unique CSC
niche mechanisms is an immediate priority to facilitate the
development of more effective GBM therapies. To identify CSC
niche adhesion mechanisms, we performed an unbiased flow
cytometry screen of cell adhesion receptors expressed in pa-
tient-derived GBM cells with a link to patient survival. Combining
additional biochemical, molecular, and biological analyses, we
identified junctional adhesion molecule A (JAM-A) as a critical
maintenance factor for CSCs.
RESULTS
Flow Cytometry Screen of Adhesion Receptors Reveals
that GBM Cells Express JAM-A
Unbiased screening approaches present an opportunity to
understand the complexity of a system as well as identify new
regulatory nodes that can be then further developed for targeting
purposes. In the context of GBM, a variety of genetic (RNAi) and
pharmacological (small molecule) screens have been performed
that have identified targets for further investigation (Hubert et al.,
2013; Visnyei et al., 2011; Wurdak et al., 2010). Whereas these
approaches have revealed the complexity of GBM and provided
targets, they have provided limited information with respect
to niche interaction. Flow cytometry enables the prospective
enrichment of CSCs and can be utilized to study intact cells as
well as specific cell-surface interactions. To identify cell-adhe-
sion receptors expressed on the surface of GBM cells, we
performed a high-throughput flow cytometry screen, which
informed the identification of cell-surface antigens differentially
expressed during neural differentiation (Yuan et al., 2011). To
perform the screen, we utilized six different GBM specimens
that had validated differences in self-renewal both in vitro (Fig-
ure S1A) and in vivo based on previously reported cell surface
markers (Eyler et al., 2011; Guryanova et al., 2011; Lathia
et al., 2010; Singh et al., 2003). Each specimen was uniquely
identified using a bar-coding approach, and then all six xeno-
grafts were pooled together for the screening procedure (Fig-
ure 1A). Along with interrogating the cell-surface expression of
adhesion receptors, we combined the analysis with a bioinfor-
matics evaluation of patient survival to identify adhesion recep-
tors that were expressed on GBM cells and informative for
patient prognosis (Figure 1A). Screening was performed on
cell-adhesionmolecules for which antibodies were commercially
available, and any that were expressed above a level of 5% for
three of the six GBM specimens were subsequently evaluated
for a negative correlation to glioma patient survival based oniplex Flow Cytometry Identifies Cell-Adhesion Receptors Negatively
reening method based on bar-coding multiple GBM specimens and screening
patient survival.
raft T4121, antigen of interest shown in blue, isotype control shown in red, and
lar generated from the NCI REpository for Molecular BRAin Neoplasia DaTa
dt/) for the 2-fold upregulated (red) and intermediate (black) groups. Log rank
ed for each adhesion molecule.
3 from the human protein atlas (http://www.proteinatlas.org) for the cortex,
individual indicated directly on the micrographs.
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the National Cancer Institute REpository for Molecular BRAin
Neoplastic Data (NCI REMBRANDT) database (Figures 1B and
1C). Our screen identified nine cell-adhesion receptors that
met the selection criteria and were ranked based on negative
correlation to glioma patient survival (Table S1) with varying
correlation between individual targets (Figure S1B). The screen
revealed the following cell-surface adhesion receptors: CD321
(JAM-A), CD63 (a Tetraspanin family member), CD87 (urokinase
receptor), CD49e (integrin a5), CD26 (dipeptidyl peptidase-4),
CD54 (ICAM1), CD29 (integrin b1), CD44 (a hyaluronic acid
receptor), and CD49f (integrin a6). Among the list were three pre-
viously published CSC markers, CD49f and CD29 (Lathia et al.,
2010) as well as CD44 (Anido et al., 2010; Jijiwa et al., 2011),
providing evidence that our approach was capable of identifying
functionally relevant adhesion receptors. CD26, a regulator of
colon CSC metastasis that interacts with integrin b1 (Pang
et al., 2010), was also identified, and CD87, which is linked to
GBM survival (Hu et al., 2011) and invasion (Raghu et al.,
2011), was likewise identified. The top two targets, CD321 and
CD63, were further validated with respect to tumor-specific
expression using the human protein atlas (Figure 1D).
JAM-A, which had a median survival of 13.4 months, was of
interest based on its reported role in cell-to-cell adhesion and
facilitation of integrin signaling (McSherry et al., 2011; Severson
et al., 2009). These functions have not been previously tested in
GBM and are likely to be an important mechanism by which cells
communicate with niche’s ECM. In the nervous system, integrin
a6 predominantly uses integrin b1 as a binding partner to initiate
signaling events upon activation (Lathia et al., 2007; Loulier et al.,
2009). We previously demonstrated that integrin a6 expression
can enrich for CSCs (Lathia et al., 2010). Further evaluation of
the activation state of integrin b1 revealed that it was also
informative for sphere-formation potential and indeed blocking
integrin b1 attenuated sphere formation (Figures S1C–S1E).
Integrin b1 is regulated by a variety of coreceptors that are cell
type and context dependent. In the mammary epithelium, where
integrins a6 and b1 are also elevated in normal and neoplastic
stem cells (Ali et al., 2011; Shackleton et al., 2006; Stingl et al.,
2006), JAM-A interacts with integrin b1 and correlates with
poor patient prognosis (McSherry et al., 2011; Murakami et al.,
2011). Given the relationship between integrin b1 and JAM-A
in the mammary gland, we wanted to determine the role of
JAM-A in GBM and its role in regulating CSC maintenance.
JAM-A Is Elevated in CSCs
To confirm that JAM-A was expressed on GBM cells and
exclude the contribution of nonneoplastic cells, we performed
flow cytometry analyses on xenografted (T4121 and T387)
specimens and a primary-patient-derived specimen (CCF2418)
in combination with known endothelial cell markers (CD105
and CD31 [data not shown]). JAM-A was expressed in xeno-
grafted and primary GBM specimens on both endothelial and
nonendothelial cells (Figure S2A). To verify that JAM-A-posi-
tive/endothelial-cell-marker-negative cells were tumor cells, we
isolated these cells from GBM xenografts and confirmed their
tumor cell origin by fluorescence in situ hybridization (FISH)
(Figures S2B and S2C). Taken together, these results confirm
that JAM-A is expressed in GBM cells.120 Cell Reports 6, 117–129, January 16, 2014 ª2014 The AuthorsTo validate our flow cytometry screen findings, we evaluated
JAM-A expression by immunofluorescence analysis on cryosec-
tions from intracranial GBMxenografts. JAM-Awas expressed in
a fraction of tumor cells (T387: 28.8%; T3691: 28.1%; T4121:
32.7%; data not shown), and colabeling revealed that a large
fraction of JAM-A-positive cells expressed CSC markers Sox2
or integrin a6 (Figures 2A and 2B; T387: 97.0%; T3691: 92.6%;
T4121: 97.3%; data not shown). The coexpression of JAM-A
with integrin a6was further confirmed by flow cytometry analysis
of xenografted patient specimens (T4121 and T387) as well as
primary GBM specimens (1217 and 1221) and found to be at
least 70% or higher (data not shown). These data suggest that
JAM-A may be elevated in CSCs. To directly evaluate this possi-
bility, we evaluated JAM-A expression by immunoblotting, flow
cytometry and immunostaining analysis. Immunoblotting anal-
ysis of matched CSCs and non-CSCs from a GBM patient xeno-
graft enriched on the basis of a cell-surface marker previously
shown to distinguish tumor formation potential (Eyler et al.,
2011; Guryanova et al., 2011; Lathia et al., 2010; Li et al., 2009)
revealed that JAM-A was elevated in the CSC-marker-positive
population as compared with the matched CSC-marker-nega-
tive population from the same GBM xenograft (Figure 2C). The
differential expression of JAM-A between CSCs and non-CSCs
was also confirmed by flow cytometry analysis comparing
parental xenografted GBM cells to CSCs enriched from the
resulting xenografts and propagated as CSC-enriched sphere
cultures (Figure 2D). The coexpression between JAM-A and
integrin a6 in CSC-enriched sphere cultures was confirmed by
immunofluorescence analysis (Figure 2E). To evaluate if JAM-A
expression changed as a result of loss of stemness, we placed
CSC-enriched sphere cultures under a 7-day serum-induced dif-
ferentiation paradigm. During differentiation, JAM-A expression
was reduced as was the expression of CSC markers Sox2 and
Olig2 whereas the differentiationmarkersMap2 and glial fibrillary
acidic protein (GFAP) were increased (Figure 2F). These data
verify that the expression of JAM-A is enriched in CSCs as
compared to their non-CSC counterparts and is suppressed dur-
ing differentiation.
JAM-A Is Not Expressed by NPCs and Is Not Required for
NPC Proliferation
Our results suggest that JAM-A is expressed on a fraction of
GBM cells positive for CSC markers and encourage the evalu-
ation of the expression profile of JAM-A in normal tissue in
order to facilitate therapeutic approaches. To evaluate the
expression and importance of JAM-A in normal neural func-
tion, we evaluated both human and mouse normal brain
tissues for JAM-A expression. To evaluate the expression of
JAM-A in human brain, we utilized both cultured fetal neural
progenitor cells (NPCs) as well as an immunohistochemistry
approach of adult brain tissue. Immunoblotting of NPCs and
GBM cells (matched CSCs and non-CSCs) confirmed that
JAM-A expression was elevated in CSCs and low in NPCs
(Figure S2D). Using an immunohistochemistry analysis, we
observed limited staining in the cortex or white matter areas
of human adult brain (Figures S2E and S2F). JAM-A staining
in the subependymal/subventricular zone (SEZ/SVZ) was
limited to the ependymal cell layer (Figure S2G). To determine
Figure 2. JAM-A Is Elevated in CSCs
(A and B) Confocal micrographs show that JAM-A
is coexpressed with CSC markers Sox2 (A) and
integrin a6 (B) on GBM cells within an intracranial
xenograft (T4121) using antibodies against JAM-A
(green) and costainedwith Sox2 (red) or integrin a6
(red). Areas of interest are indicated by yellow
arrow and shown at higher power, and the scale
bar represents 50 mm.
(C) JAM-A is elevated in CSCs (enriched by cell
surface expression of CD133 from GBM xenograft
tumor T4121) as compared with matched non-
CSCs as shown in representative immunoblots
that show separation between populations with
respect to Sox2 and Olig2.
(D) Bar graphs summarizing flow cytometry
analyses between parental cells and CSCs
demonstrate that CSCs have significantly higher
expression of JAM-A as compared to parental
unenriched tumor cells from GBM xenografts
(T3691, T387, T4121, and T4302).
(E) CSCs grown in sphere culture (from tumor
T4121) coexpress JAM-A (green) and integrin a6
(red) as shown in confocal micrographs. An area
of interest indicated by white box is shown with
enlarged images below, nuclei were counter-
stained with Hoechst 33342, and scale bar rep-
resents 50 mm.
(F) Upon CSC differentiation (enriched from GBM
xenograft tumor T4121) using a 10% fetal bovine
serum (FBS) differentiation paradigm over a 7-day
period, JAM-A expression is suppressed with
concomitant loss in CSC markers Sox2 and Olig2
and an increase in differentiation markers GFAP
and Map2 as shown in representative immuno-
blots.
Data for bar graphs displayed as mean values ±
SD, blue value represents fold change, and ***p <
0.001 as assessed by one-way ANOVA. See also
Figure S2.relative levels of JAM-A expression, we also utilized grade II
astrocytoma and GBM tissue and observed low but detectable
staining in grade II tumors and strong staining in GBM tissue
(Figures S2H–S2J).
JAM-A knockout mice are viable, although the birth ratios are
not Mendelian (1 [+/+]: 1.7 [+/]: 0.6 [/]), and their endothelial
cells display a fibroblast growth factor 2-induced angiogenesis
defect (Cooke et al., 2006). However, the impact of JAM-A
deletion in the brains of these mice is yet to be determined.
To determine the role of JAM-A in NPCs, we evaluated
proliferation in a key neurogenic niche (Alvarez-Buylla and
Lim, 2004) in the brains of wild-type and JAM-A / mice,
the SVZ adjacent to the lateral ventricles. Analysis of SVZ
proliferation using two molecular markers (proliferating cell
nuclear antigen [PCNA] and phosphohistone H3 [PH3])
revealed no differences between adult wild-type (WT) andCell Reports 6, 117–129JAM-A / mice (Figures 3A–3C)
suggesting that JAM-A is not essential
for NPC proliferation.
JAM-A has previously been reported
to be expressed in the mouse corpuscallosum on NG2-expressing cells (Stelzer et al., 2010), likely
to be glial progenitors and pericytes. However, the expression
in the neurogenic niches or NPCs is yet to be determined. The
JAM-A antibody used only stained JAM-A expression in WT
mice, but not in JAM-A / mice confirming the specificity of
the JAM-A antibody (Figure 3D). JAM-A expression did not
overlap with NPCs and astrocytes (marked by GFAP; Figure 3E),
NPCs (marked by Sox2; Figure 3F), or neuroblasts (marked
by doublecortin, Dcx; Figure 3G). JAM-A expression, how-
ever, was detected in the SVZ and was found to overlap with
Iba1-positive cells, reported to be putative microglia and
macrophages (Figure 3H). Iba1-positive cells were detected in
both WT and JAM-A / mice, suggesting that the genesis
of microglia and macrophages is not dependent on JAM-A
(Figures S3A and S3B). JAM-A was not detected on additional
SVZ components (ependymal cells, blood vessels, and glial, January 16, 2014 ª2014 The Authors 121
Figure 3. JAM-A Is Not Required for Neurogenesis
(A–C) No detectable difference was observed in SEZ/SVZ proliferation between wild-type (WT) and JAM-A / mice as shown in summary bar graphs (A) and
confocal micrographs of proliferation markers PCNA (B) and PH3 (C).
(D) Confocal micrographs show specific staining for JAM-A antibody in the SEZ/SVZ of WT mice but no staining in JAM-A / mice.
(E–H) Analysis of the mouse SEZ/SVZ reveals that JAM-A (green) is present in the SEZ/SVZ and not on NSCs/astrocytes (stained with an antibody against GFAP,
red [E]), NSC/NPCs (stained with an antibody against Sox2, red [F]), or neuroblasts (stained with an antibody against Dcx, red [G]) but on microglia and
macrophages (stained with an antibody against Iba1, red [H]) as shown in confocal micrographs. Areas of interest are indicated by yellow arrow and areas shown
as insets. In (F), another example of JAM-A-positive, Sox2-negative cell is indicated by a white arrow. Nuclei were counterstained with Hoechst 33342 and the
scale bar represents 25 mm.
Data for bar graphs are displayed as mean values ± SD. See also Figure S3.progenitors) or proliferating cells (Figures S3C–S3F). JAM-A
was also not detected on additional cell types in another
neurogenic niche, the subgranular zone (SGZ) of the dentate
gyrus in the hippocampus, with the exception of microglia
and macrophages (Figures S3G–S3J). Our analysis of
the neurogenic regions in the mouse brain revealed that in122 Cell Reports 6, 117–129, January 16, 2014 ª2014 The Authorsthe SVZ and SGZ, JAM-A was only coexpressed with Iba1-
positive cells (Figures S3K and S3L) and that JAM-A /
does not affect lba1+ cell genesis. Taken together, our human
and mouse analysis suggests that JAM-A is not highly
expressed on NPCs and not likely to be essential for their
function.
Figure 4. Targeting JAM-A by Blocking An-
tibodies Decreases Growth, Self-Renewal,
and Adhesion and Increases Apoptosis of
CSCs but Does Not Impact Survival of
Nonstem Tumor Cells or NPCs
JAM-A-blocking antibody (red line/red bar) was
used to treat CSCs (enriched from GBM xeno-
grafts T4121 and T387) andmatched non-CSCs at
10 mg/ml as compared to a control antibody (black
line/black bar).
(A–D) A strong decrease was seen in CSC growth
over time (A and C) but was not observed in non-
CSCs (B and D). Ab, antibody.
(E and F) An attenuation in self-renewal as
assessed by sphere formation was observed in
CSCs in the presence of the JAM-A-blocking
antibody.
(G and H) A significant reduction in CSC adhesion
onto a tumor ECM (Geltrex) was also observed
with the JAM-A-blocking antibody as well as an
integrin-a6-blocking antibody.
(I–K) Apoptosis induced by the JAM-A-blocking
antibody in CSCs (I and J) was not observed in
NPCs (K).
Data for all graphs displayed asmean values ±SD;
*p < 0.05, **p < 0.01, and ***p < 0.001 as assessed
by one-way ANOVA. See also Figure S4.Targeting JAM-A by Blocking Antibody Attenuates CSC
Growth, Self-Renewal, and Adhesion but Does Not
Affect Non-CSCs or NPCs
Our analysis confirmed the expression of JAM-A on CSCs and
the very low or nondetectable levels of expression in matched
non-CSCs or NPCs, supporting the hypothesis that JAM-A is
primarily utilized by CSCs. To evaluate the impact of disrupting
JAM-A on CSC growth, we utilized a blocking antibody. CSCs
treated with the JAM-A-blocking antibody at previously reported
concentrations of 1 and 10 mg/ml (Severson et al., 2009) showed
significant reduction in growth over a 7-day time course (Figures
4A, 4C, S4A, and S4C), which was not observed to the same
extent in the non-CSC population (Figures 4B, 4D, S4B, and
S4D). A longer time course (days 10–14) did reveal a significant
reduction in non-CSC growth at the 10 mg/ml, but not the
1 mg/ml antibody concentration (data not shown). Sphere
formation, a surrogate of self-renewal, was also significantlyCell Reports 6, 117–129attenuated in the presence of the JAM-
A-blocking antibody at both 10 mg/ml
(Figures 4E and 4F) and 1 mg/ml (data
not shown). To determine if the effects
of the JAM-A-blocking antibody on
CSCs are due, in part, to apoptosis, we
evaluated caspase 3/caspase 7 activity
and found a significant increase in CSCs
at both concentrations of the JAM-A
blocking-antibody (Figures S4E–S4H).
For equivalent conditions tested for non-
CSCs, only a significant induction of cas-
pase activity was observed from GBM
specimen T4121 at 10 mg/ml (Figure S4F),but this was 4.8-fold lower when compared to CSCs from the
same specimen. Unlike non-CSCs from GBM specimen T4121
over a longer time course, caspase 3/caspase 7 activity was
not induced by the JAM-A blocking antibody at both concentra-
tions in non-CSCs from T387 (Figures S4G and S4H). A key
function of JAM-A is to stabilize integrins and thereby facilitate
adhesion, and to evaluate if blocking JAM-A compromised this
function, we performed short-term adhesion assays. Using a
representative tumor ECM enriched in laminins (Geltrex), we
found that the JAM-A-blocking antibody significantly inhibited
cell adhesion to the matrix (Figures 4G and 4H), which was phe-
nocopied with an integrin-a6-blocking antibody (Figures 4G and
4H). These differences in adhesion were not observed when
assays were performed on fibronectin, another ECM protein,
suggesting that JAM-A-mediated adhesion is laminin-specific.
Finally, to determine if the JAM-A-blocking antibody induced
apoptosis in NPCs, we evaluated CSCs and NPCs treated with, January 16, 2014 ª2014 The Authors 123
Figure 5. Targeting JAM-A by RNAi
Decreases Stem Cell Expression, Growth,
Self-Renewal, and Tumor Formation Ca-
pacity of CSCs
(A) Two independent shRNA constructs (knock-
down [KD] 1 and 2) were generated against JAM-
A, and reduced JAM-A expression as compared to
nontargeting controls was verified in CSCs from
GBM xenograft T4121 by flow cytometry.
(B) Attenuation of JAM-A in CSCs (enriched from
GBM xenograft T4121) results in a decrease in
integrin b1 expression as well as other core CSC
markers (Sox2, Olig2) as shown by immunoblots.
(C and D) Reduction of JAM-A in CSCs (enriched
from GBM xenograft T4121) also resulted in
decreased self-renewal (C) and CSC growth (D).
(E and F) Slower tumor growth after grafting CSCs
(enriched from GBM xenograft T4121) was also
observed when JAM-A expression was attenuated
by shRNA (E), and overall tumor size was reduced
as shown in bar graphs and images from brain
sections 30 days after transplantation of 1,000
CSCs (F).
Data for all graphs displayed asmean values ± SD;
*p < 0.05, **p < 0.01, and ***p < 0.001 as assessed
by one-way ANOVA. For multiple groups, #p <
0.05, ##p < 0.01, and ###p < 0.001—NT versus
KD1; *p < 0.05, **p < 0.01, and ***p < 0.001—NT
versus KD2; and p < 0.05—KD1 versus KD2 as
assessed by one-way ANOVA.10 mg/ml of the JAM-A blocking antibody and observed a signif-
icant induction of cleaved caspase 3 by flow cytometry only in
CSCs, but not in NPCs (Figures 4I–4K) measured after 3 days.
Taken together, these data suggest that blockade of JAM-A
in CSCs attenuates growth, self-renewal, and adhesion and
induces cell death while leaving non-CSCs and NPCs intact.
Genetic Disruption of JAM-A Results in Decreased CSC
Growth, Self-Renewal, and Tumor Formation
Acute disruption of JAM-A by a blocking antibody compromised
CSC adhesion, growth, and self-renewal. To confirm the role of
JAM-A in CSCmaintenance, we also utilized a genetic approach
to attenuate JAM-A expression by RNAi. We developed two
independent, nonoverlapping small hairpin RNA (shRNA) con-
structs to knockdown JAM-A (knockdown 1 [KD1] and KD2).
When compared to a nontargeting (NT) control construct, both
JAM-A knockdown constructs reduced JAM-A expression levels
as evaluated by quantitative PCR (qPCR) (data not shown), flow
cytometry (Figure 5A), and immunoblotting (Figure 5B). JAM-A124 Cell Reports 6, 117–129, January 16, 2014 ª2014 The Authorsplays a major role in integrin stabilization
(Severson et al., 2009), and knockdown
of JAM-A resulted in reduced expression
of integrin b1 (Figure 5B). In addition, flow
cytometry analysis revealed a reduction
in integrin a6 cell surface levels after
JAM-A knockdown (data not shown),
further supporting a role for JAM-A in
integrin stabilization. CSCs with attenu-
ated JAM-A also displayed deficienciesin sphere formation (Figure 5C) and proliferation (Figure 5D). To
evaluate if JAM-A was required for tumor formation, the key
functional criteria for a CSC, we transplanted NT or KD CSCs
into the brain of immunocompromised mice and observed
significantly less tumor formation with JAM-A-deficient CSCs
(Figure 5E). Additionally, analysis of mice 30 days after CSC
transplantation revealed significantly smaller tumor area in the
mouse brains receiving JAM-A knockdown CSCs than in the
ones receiving CSCswith NT construct (Figure 5F). These results
indicate that JAM-A is critical for integrin stabilization and that
attenuation of JAM-A results in a deficiency of CSC phenotypes,
including growth, self-renewal, and tumor formation.
JAM-A Expression Is Informative for Tumor Grade and
Patient Prognosis
The molecular genetics of GBM have been extensively investi-
gated permitting the association between gene profiles and pa-
tient outcome (Brennan et al., 2013; Cancer Genome Atlas
Research Network, 2008; Frattini et al., 2013; Phillips et al.,
Figure 6. JAM-A Correlates with Glioma
Malignancy and Is Informative for Patient
Survival
(A and B) Box and whisker plots of expression
level for JAM-A using Oncomine (https://www.
oncomine.org/) demonstrates significantly higher
expression (p < 0.001 as assessed by one-way
ANOVA) of JAM-A in glioblastoma tissue than in
neural progenitor cells (A) and significantly higher
expression (p < 0.001 as assessed by one-way
ANOVA) of JAM-A in glioblastoma tissue as
compared with oligodendroglia (Oligo) tumors,
low-grade astrocytoma, or mixed glioma and as-
trocytoma (B).
(C) JAM-A is also informative for GBM patient
survival as demonstrated by Kaplan-Meier survival
plots. The red line indicates the high expression
group (ten patients) with greater than one SD
above the mean of all patients. The blue line in-
dicates the low expression group (nine patients)
with greater than one SD below the mean of
all patients. The black line indicates the group
(57 patients) within one SD of mean.
(D and E) Kaplan-Meier survival plots for glioma (D)
and GBM (E) patients with differential tumor
JAM-A expression using the NCI REMBRANDT
database at a level of 2-fold upregulation indicates
that JAM-A levels inversely correlates with patient
survival (red line indicates 2-fold upregulation
[137 glioma patients, 70 GBM patients], blue line
indicates 2-fold downregulation [eight glioma
patients], and black line represents intermediate
expression [198 glioma patients, 110 GBM
patients]).
(F and G) Analysis of JAM-A using histochemical
staining in a patient data set (Odense data set,
Odense University Hospital Denmark) indicates
that JAM-A is elevated in GBM as compared to
normal brain controls (F) and that high-JAM-A
expression correlates with poor patient prognosis
([G]; 102 patients in the JAM-A-high group and 83
patients in the JAM-A-low group).
Data for all graphs displayed asmean values ±SD;
**p < 0.01 and ***p < 0.001 as assessed by one-
way ANOVA. For survival analysis, the log rank
p value for significance of difference between
groups is indicated on each individual graph. See
also Figure S5.2006; Verhaak et al., 2010). To evaluate the relationship between
JAM-A and GBM patient survival and determine if JAM-A was
informative for tumor grade and patient prognosis, we interro-
gated brain tumor bioinformatics databases. To determine if
elevated JAM-A expression was restricted to GBM or also pre-
sent in other neural cell types, such as NPCs, we evaluated the
Lee data set (Lee et al., 2006) from Oncomine and observed a
significantly higher level of JAM-A in GBM as compared to
NPCs (Figure 6A). Evaluation of JAM-A expression in relation
to tumor grade from the Freije data set (Freije et al., 2004) in
the Oncomine database indicated a significant elevation of
JAM-A expression in GBM as compared to lower-grade tumors
(oligodendroglioma, mixed glioma, grade III astrocytoma; Fig-
ure 6B). Kaplan-Meier analysis also indicated that high-JAM-A
expression (at least one SD above the mean) correlated withCpoor survival, whereas low-JAM-A expression (at least one SD
below the mean) correlated with better survival in the Phillips
data set (Phillips et al., 2006) from Oncomine (data not shown).
Likewise, JAM-A informed poor patient prognosis in GBM from
the same data set (Figure 6C). We further confirmed the associ-
ation between JAM-A expression and glioma patient survival
using the NCI REMBRANDT database and found that high-
JAM-A expression (>2-fold) correlated to poor glioma patient
survival whereas low-JAM-A expression (<2-fold) correlated to
increased patient survival (Figure 6D). The correlation between
elevated JAM-A expression and poor patient prognosis was
observed in GBM patients as well (Figure 6E). To determine if
these differences in survival were specific to JAM-A or shared
by the other JAM family members, JAM-B and JAM-C, we
evaluated the REMBRANDT database and Phillips data set inell Reports 6, 117–129, January 16, 2014 ª2014 The Authors 125
Oncomine and found neither isoform was informative for glioma
or GBM patient prognosis (Figure S5). Taken together, our
bioinformatics analysis reveals that JAM-A is associated with
increased malignancy and poor patient prognosis.
The ability for a biomarker to provide informative molecular
diagnosis is useful and is further enhanced by its capacity to
inform survival based on protein expression. Using immunohis-
tochemical approaches, we observed that JAM-A expression
increased with malignancy and was elevated in GBM tissue
as compared to nonneoplastic cortical tissue (Figures 1D, 6F,
and S2E–S2J). We examined the capacity of JAM-A protein
expression to predict GBM patient outcome in a clinically anno-
tated data set (Dahlrot et al., 2013). High-JAM-A protein level
also significantly correlated to poor GBM patient prognosis
as compared with low-JAM-A expression (Figure 6G). Taken
together, our findings demonstrate that JAM-A is increased
with malignancy and is a negative indicator of patient prognosis.
DISCUSSION
The ability for a stem cell to interact with its niche through adhe-
sion mechanisms enables it to maintain a physical location as
well as receive specialized signals from the niche (Spradling
et al., 2001). Adhesion receptors are essential transducers of
this process and facilitate niche adhesion as well as stem-cell-
maintenance signaling. Adhesion receptor expression has
been used to prospectively enrich them from normal and
neoplastic tissues, including the breast (Ali et al., 2011; Shackle-
ton et al., 2006; Stingl et al., 2006; Vaillant et al., 2008) and brain
(Hall et al., 2006; Lathia et al., 2010). Stem cell niches, them-
selves, also contain unique ECM expression, which for the brain
includes elevated laminin expression (Lathia et al., 2007, 2012).
The close association of adhesion to stem cell maintenance is
further supported by functional studies targeting niche adhesion
that results in stem cell detachment and subsequent differentia-
tion and /or death (Georges-Labouesse et al., 1998; Graus-Porta
et al., 2001; Loulier et al., 2009; Niola et al., 2012). Whereas the
majority of niche adhesion studies involve adhesion receptors,
such as integrins or CD44. Here, we provide evidence that
JAM-A promotes CSC maintenance in GBM, and our results
pose several outstanding questions. Why is JAM-A elevated in
GBM? Why might JAM-A be useful to CSCs rather than other
adhesion molecules? Possible explanations include the neces-
sity to form cell-cell contacts within a GBM to promote tumor
progression and the need for CSCs to directly interact with other
cells within the niche.
JAM-A is considered to be an epithelial marker as it is ex-
pressed at tight junctions and regulates cell-cell adhesion (Sev-
erson and Parkos, 2009). The JAM family members play a variety
of roles in normal and neoplastic processes, including angiogen-
esis (Naik et al., 2008), leukocyte migration (Wojcikiewicz et al.,
2009), platelet activation (Naik et al., 2012), and the regulation
of cell morphology and polarity (Rehder et al., 2006). JAMs can
execute these programs by several methods, including adjacent
cell JAM-to-JAM interaction, stabilization of integrins on the
same cell, or the direct interaction of integrins on an adjacent
cell (Severson and Parkos, 2009). There are conflicting reports
as to the role of JAM-A in breast cancer progression, with evi-126 Cell Reports 6, 117–129, January 16, 2014 ª2014 The Authorsdence to suggest that loss of JAM-A increases migration and
invasion (Naik and Naik, 2008), whereas others suggest that
JAM-A is increased during tumor cell migration and adhesion
(McSherry et al., 2011). Our work suggests that in CSCs,
JAM-A is instrumental in regulating stabilization of integrins on
the same cell, although interaction of JAM-A dimers between
adjacent CSCs as well as JAM-A-integrin interactions with adja-
cent cells may also be possible and may contribute to the regu-
lation of CSC maintenance by JAM-A. Future studies expanding
the signaling network of JAM-A regulation in CSCs is likely to
connect it to other key GBM pathways as well as other stem
cell processes, such as epithelial-to-mesenchymal transition.
In addition, future studies focusing on the transcriptome, cell
cycle, and cell division mode changes as a result of JAM-A tar-
geting are likely to identify additional mechanisms governing
JAM-A function in CSCs. Further interrogation of JAM-A function
in CSCs from other advanced cancer may also demonstrate a
conserved role for JAM-A in CSC maintenance.
Given the importanceof adhesion in stemcellmaintenance, the
question arises whether this process can be targeted in CSCs.
This therapeutic paradigm is not without complexity and chal-
lenges as many adhesion mechanisms, including integrins,
are present in both normal and neoplastic stem cells (Hale
et al., 2012). Alternative strategies to develop CSC antiadhesion
therapies include the identification of coreceptors and/or other
signaling pathway members unique to the CSC population.
With this goal in mind, our studies demonstrate that JAM-A is
specifically used by CSCs to maintain integrin b1 activation and
promote stem cell maintenance. Moreover, targeting of JAM-A
compromises CSC growth but does not adversely impact non-
CSCs or NPCs, suggesting that only tumor cells at the top of
the cellular hierarchy are sensitive to JAM-A inhibition. These
dataprovidea rationale for furtherevaluationof JAM-A inaclinical
setting. Taken together, ourdatademonstrate thatCSCspossess
specific cell-adhesion mechanisms to regulate their self-renewal
and can be targeted with limited disruption to the normal tissue,
representing a promising anti-GBM therapeutic paradigm.
EXPERIMENTAL PROCEDURES
CSC Derivation, Culture, and Analysis
Human GBM cells were derived under written informed consent and approved
institutional review board protocols from Cleveland Clinic (CCF2352 and
CCF2418), University Hospitals-Seidman Cancer Center at Case Western
Reserve University (1217 and 1221) for experimental analysis, and from
Duke University to establish xenografts in BalbC nu/nu (athymic nude) mice
for maintenance of the tumor hierarchy as previously published (Bao et al.,
2006; Eyler et al., 2011; Guryanova et al., 2011; Lathia et al., 2010; Li et al.,
2009). All procedures involving mice were done under an approved Cleveland
Clinic Institutional Animal Care and Use Committee protocol. GBM xenografts
for four tumors (T3691, T387, T4121, and T4302) were used for experimental
studies. Only low (<5) passage cells were used for analysis to minimize cellular
drift, and the majority of cells were used immediately after dissociation. Disso-
ciation and culture of cells was done as previously described (Bao et al., 2006;
Eyler et al., 2011; Guryanova et al., 2011; Lathia et al., 2010; Li et al., 2009) and
detailed in the Supplemental Information.
Flow Cytometry Screening
Flow cytometry screening was done as previously described with the BD
Lyoplate system (Yuan et al., 2011), and additional parameters are provided
in the Supplemental Information.
Database Mining and Processing
To further refine the flow cytometry screen and interrogate the association
of JAM-A to GBM patient survival, the following databases were used: NCI
REpository for Molecular BRAin Neoplasia DaTa bioinformatics database
(https://caintegrator.nci.nih.gov/rembrandt/; REMBRANDT), human protein
atlas (http://proteinatlas.org), The Cancer Genome Atlas (TCGA) data
(accessed at https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp), and Onco-
mine (Compendia Bioscience; http://www.oncomine.org). Relevant analytical
parameters are provided in the Supplemental Information.
Flow Cytometry Analysis and FISH
For flow cytometry analysis, GBM cells were dissociated from patient speci-
mens or xenografts, recovered overnight in supplemented neurobasal media,
and sorted on a BD FACS Aria II as previously described (Lathia et al., 2010)
using the following antibodies: JAM-A-PE (BD Biosciences), CD31-FITC (BD
Biosciences), and CD105-FITC (BD Biosciences). Appropriate isotype control
antibodies were used to set gates and live/dead determination was based
on 7AAD exclusion (BD Biosciences). Additional flow cytometry analysis
was done with JAM-A and an integrin a6-FITC antibody (BD Biosciences).
JAM-A-positive/CD105-negative cells were collected for fluorescence in situ
hybridization of chromosome 7 and epidermal growth factor (EGFR) using a
Vysis EGFR/CEP 7 FISH Probe Kit (Abbott Molecular) as per the manufac-
turers’ protocol. Images were taken with a 633 oil immersion objective using
a Leica widefield microscope and images were processed and assembled in
Photoshop (Adobe).
Immunoblotting Analysis
Protein analysis was done by immunoblotting as previously described (Eyler
et al., 2011; Guryanova et al., 2011; Li et al., 2009). Briefly, 10 mg of total protein
was loaded per condition and probed using the following antibodies: JAM-A
(Santa Cruz Biotechnology, 1:1,000), Sox2 (Sigma-Aldrich, 1:1,000), integrin
a6 (Cell Signaling Technologies, 1:1,000), integrin b1 (Millipore, 1:1,000),
Olig2 (Millipore, 1:1,000), GFAP (Sigma, 1:1,000), Map2 (Covance, 1:1,000),
Actin (Santa Cruz Biotechnology, 1:2,500), and a-tubulin antibody (Sigma-
Aldrich, 1:500) was used as a loading control. Species-specific horse-
radish peroxidase-conjugated secondary antibodies were used for detection
(Invitrogen, 1:2,000).
Immunostaining and Immunohistochemical Analysis
Immunostaining analysis on xenografted GBM specimens (generated by intra-
cranial injection of GBM specimen T4121) or tumorspheres was done as pre-
viously described (Lathia et al., 2010) using 10 mm frozen sections obtained
from the Duke University Brain Tumor Center Tissue Bank and histologically
confirmed by a neuropathologist (R.E.M.) using antibodies against integrin
a6 (Millipore, 1:100), integrin b1 (Millipore, 1:100), Sox2 (R&D Systems,
1:200), and JAM-A (Santa Cruz Biotechnology, 1:50) and species-appropriate
secondary antibodies (Alexa 488, 568, or 633; Invitrogen, 1:200). Nuclei were
counterstained with Hoechst 33342 (1:1,000 dilution from a 5 mg/ml stock so-
lution; Invitrogen). All confocal imaging was done using a Leica SP-5 confocal
microscope as described previously (Lathia et al., 2010), and images were pro-
cessed and assembled in Photoshop (Adobe). Immunohistochemical analysis
was done using standard procedures (Li et al., 2009), and details are provided
in the Supplemental Information.
JAM-A Null Mice and Mouse Histological Analysis
JAM-A null (/) and wild-type (WT) control mice were obtained from
the University of Delaware and generated as previously described (Cooke
et al., 2006). For histological analysis of PCNA and PH3, six age-matched
JAM-A / and WT were evaluated at three anatomical depths per brain for
the SVZ and dentate gyrus. For expression analysis, the following antibodies
were used: JAM-A (Santa Cruz Biotechnology, 1:100), PCNA (Abcam,
1:200), PH3 (Millipore 1:500), Doublecortin (Dcx; Cell Signaling, 1:100), Sox2
(R&D Systems, 1:200), GFAP (Dako, 1:200), Iba1 (Millipore, 1:200), S100b
(Dako, 1:200), collagen IV (Millipore, 1:500), NG2 (Millipore, 1:100), and
NeuN (Millipore, 1:200). Nuclei were counterstained with Hoechst 33342
(1:1,000 dilution from a 5 mg/ml stock solution; Invitrogen). All imaging was
done using a Leica SP-5 confocal microscope as described previously (LathiaCet al., 2010), and images were processed and assembled in Photoshop
(Adobe).
ECM Adhesion Assays
To evaluate adhesion, CSCs were trypsinized and allowed to recover for a
minimum of 5 hr. Subsequently, CSCs were plated at 100,000 cells per well
in a 24-well plate and treated overnight with either 10 mg/ml immunoglobulin
G1 (IgG1) control antibody (Millipore), 10 mg/ml JAM-A-blocking antibody
(Santa Cruz Biotechnology), or 10 mg/ml GoH3 integrin-a6-blocking antibody
(Millipore). Cells were transferred to a 6-well plate coated with Geltrex
(24 mg/ml) or fibronectin (10 mg/ml), as per manufacturer’s instructions, and
allowed to adhere for 30 min at 37C. Following adhesion, wells were washed
with neurobasal medium and cells were fixed with 4% paraformaldehyde for
15 min at room temperature. After two washes with 13 PBS, nuclei were
counterstained with DAPI or propidium iodide (1:1,000). Cells were imaged
using the well plate acquisition tool on a Hamamatsu C9100 imaging system.
The number of cells adhered to each well were quantified using ImageJ soft-
ware. Values are expressed in comparison to the nonimmune IgG1-treated
samples, which were set to a relative value of 1.
JAM-A Lentiviral shRNA and Overexpression Construct Production
Lentiviral shRNA constructs were prepared as we previously reported (Eyler
et al., 2011; Guryanova et al., 2011; Lathia et al., 2010; Li et al., 2009). In short,
using Lipofectamine 2000 (Invitrogen), 293FT cells were cotransfected with
packaging vectors psPAX2 and pCI-VSVG (Addgene) and lentiviral vectors di-
recting expression of shRNA (Sigma) specific to JAM-A (TRCN0000061649
[KD1] and TRCN0000061650 [KD2]) or a nontargeting control (NT) shRNA
(SHC002) to produce virus. Media of the 293FT cell cultures were changed
18 hr after transfection, and viral supernatants were collected 24 and 48 hr later
and filtered for immediate use or concentrated with polyethylene glycol precip-
itation and stored at 80C for future use.
Cell Proliferation, Caspase Activity, and Tumorsphere Formation
Assays
Assessments were made as previously described (Bao et al., 2006; Eyler et al.,
2011; Guryanova et al., 2011; Lathia et al., 2010; Li et al., 2009) and outlined
in the Supplemental Information.
qPCR
qPCR analysis was performed as previously described (Wang et al., 2008)
using procedures outlined in the Supplemental Information.
In Vivo Tumor Formation Assays
For in vivo tumor formation evaluation, CSCs were transplanted into the frontal
lobe of BalbC Nu/Nu mice at 100, 1,000, or 5,000 cells per mouse and evalu-
ated as previously described (Bao et al., 2006; Eyler et al., 2011; Guryanova
et al., 2011; Lathia et al., 2010; Li et al., 2009). Additional information is
provided in the Supplemental Information.
Statistical Analysis
Reported values are mean values ± SD from studies done in at least triplicate.
Unless otherwise stated, one-way ANOVA was used to calculate statistical
significance with p values detailed in the text and figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.11.043.
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